The proceeds will be used to finance drug development works based on advances in partner institutes’ research.
Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.
Patient Square Capital led the financing round with new investors including M&G as well as two US public pension plans taking part.
The funding round also saw participation from current investor Rock Springs Capital.
Apollo plans to utilise the funds to progress its pipeline programmes through clinical development.
The proceeds will also be used to finance drug discovery and development works of the company based on developments in its partner institutes’ research.
Furthermore, the company will license or purchase further clinical-stage programmes that meet a stringent selection process.
Apollo Therapeutics CEO Dr Richard Mason said: “We are delighted to announce the close of our latest fundraise and wish to thank our existing investors for their continued support, as well as warmly welcoming all the new investors.
“Apollo has built a broad and diversified pipeline focused on major commercial markets and this latest fund-raising enables us to take our most advanced programmes to key clinical value inflection points.”
The latest funding adds to $195m in proceeds secured earlier by the company.
Apollo focuses on advancing major medical research into treatments leveraging a “hub-and-spoke” approach.
Patient Square Capital managing partner Jim Momtazee said: “I have long believed in a business model for drug development characterised by extremely talented management, sufficient capital to pursue multiple programmes and world-class science focused on unmet medical need.
“We are proud to support Apollo Therapeutics as it develops a number of promising medicines that we anticipate will eventually transform patient care.”
Source: pharmaceutical-technology.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
